Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Uncovering molecular and cellular mechanisms of immune cell trafficking across the blood-CSF barrier in autoimmunity

Project description

Profiling immune cell traffic across the blood-CSF barrier

The brain is protected from potentially harmful blood constituents in part by the blood-cerebrospinal fluid (CSF) barrier. Scientists recently discovered that this physical barrier does not prevent large immune cells from crossing as previously believed. Given that harmful immune cell trafficking is implicated in brain autoimmunity such as neuropsychiatric lupus (neuro-lupus), enhanced trafficking might be a pathway to tumour treatment or even treatments for neurodegenerative diseases. The ERC-funded CNS Hidden Door project will investigate this by leveraging their discovery of enhanced leukocyte migration through rather than between cells of the brain-CSF barrier in neuro-lupus. Using high-tech methods, they will classify cell types involved, identify trafficking pathways and develop approaches to regulate the process.

Objective

Immune cells continuously traverse our body, crossing vascular and epithelial barriers; from lymphatic organs into the blood, and from the blood into various tissues for surveillance or to fight infection. However, the brain has long been considered an immune-privileged organ. Barriers protecting the brain against infection or harmful toxic agents were also thought to block entry of immune cells, leaving immune functions to brain-resident microglia cells. This dogma was recently overturned when it became clear that immune cells cross, mainly for surveillance, especially at the Blood-CSF barrier. Furthermore, while harmful immune cell trafficking is a hallmark of brain autoimmunity, e.g. Multiple Sclerosis and Neuro-Lupus, enhanced trafficking might help to fight brain tumours, and even to resolve neurodegenerative conditions, e.g. Alzheimer’s Disease. Yet the study of immune cell trafficking across the Blood-CSF barrier is severely hampered by a shortage of suitable methodologies.
We investigated Blood-CSF barrier dysfunction in Lupus and discovered a brain lymphoid structure with enhanced immune cell trafficking. Dominant transepithelial leukocyte migration (through, rather than in between, cells) will enable us to catch the trafficking events ‘red-handed’ and to identify molecular and cellular trafficking mechanisms. Harnessing innovative methodologies involving single-cell RNAseq, Super-Resolution microscopy, Imaging cytometry, and genetic/pharmacological interventions, we aim to decipher the fundamental question of how leukocytes enter the brain. We will classify specialized immune and epithelial barrier cell types, identify trafficking molecular pathways, and develop approaches to regulate the process. We will also assess this barrier involvement in the pathobiology of human Neuro-Lupus disease.
Understanding immune trafficking mechanisms may be the key to a specialized brain portal, leading to therapeutics that can modulate brain-immune interactions.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-COG

See all projects funded under this call

Host institution

THE HEBREW UNIVERSITY OF JERUSALEM
Net EU contribution
€ 2 412 448,00
Address
EDMOND J SAFRA CAMPUS GIVAT RAM
91904 Jerusalem
Israel
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 412 448,00

Beneficiaries (1)